Literature DB >> 24139413

MiR-378 inhibits progression of human gastric cancer MGC-803 cells by targeting MAPK1 in vitro.

Bojian Fei1, Haorong Wu.   

Abstract

Gastric cancer (GC) is one of the most common cancers and the leading cause of cancer-related deaths globally. The discovery of microRNAs (miRNAs) provides a new avenue for GC diagnostic and treatment regiments. Currently, a large number of miRNAs have been reported to be associated with the progression of GC, among which miR-378 has been examined to be downregulated in GC tissues and several cell lines. However, the function of miR-378 on GC cells and the mechanisms were less known. Here we found that ectopic expression of miR-378 could inhibit cell proliferation, cell cycle progression, cell migration as well as invasion, and induced cell apoptosis in GC cell line MGC-803. Moreover, we found that oncogene mitogen-activated protein kinase 1 (MAPK1) was a target gene of miR-378 in GC cells, and the tumor-suppressive role of miR-378 might be achieved by the direct interaction with MAPK1. Taken together, our results showed that miR-378 might act as tumor suppressors in GC, and it may provide novel diagnostic and therapeutic options for human GC clinical operation in the future.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 24139413     DOI: 10.3727/096504013X13775486749254

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  51 in total

1.  MicroRNA-503 represses epithelial-mesenchymal transition and inhibits metastasis of osteosarcoma by targeting c-myb.

Authors:  Xinzhen Guo; Jie Zhang; Jianfeng Pang; Sheng He; Guojun Li; Yang Chong; Chao Li; Zhijian Jiao; Shiqian Zhang; Ming Shao
Journal:  Tumour Biol       Date:  2016-01-14

2.  Role of microRNAs in diagnosis and treatment of the pathogenesis of gastric cancer.

Authors:  Gang Chen; Yong Tang; Jiang-Hua Wu; Feng-Hua Liu
Journal:  Int J Clin Exp Med       Date:  2014-12-15

3.  miR-709 up-regulated in hepatocellular carcinoma, promotes proliferation and invasion by targeting GPC5.

Authors:  Tonggang Liu; Xuezhong Zhang; Kaihui Sha; Xianxian Liu; Liguo Zhang; Bangmao Wang
Journal:  Cell Prolif       Date:  2015-03-27       Impact factor: 6.831

4.  MicroRNA-215 acts as a tumor suppressor in breast cancer by targeting AKT serine/threonine kinase 1.

Authors:  Jian Yao; Ping Zhang; Jin Li; Wei Xu
Journal:  Oncol Lett       Date:  2017-05-17       Impact factor: 2.967

Review 5.  Circulating microRNAs and long non-coding RNAs in gastric cancer diagnosis: An update and review.

Authors:  Ya-Kai Huang; Jian-Chun Yu
Journal:  World J Gastroenterol       Date:  2015-09-14       Impact factor: 5.742

6.  MicroRNA-10b inhibits proliferation, migration and invasion in cervical cancer cells via direct targeting of insulin-like growth factor-1 receptor.

Authors:  Ren Hou; Daixian Wang; Jian Lu
Journal:  Oncol Lett       Date:  2017-04-13       Impact factor: 2.967

7.  miR-506 inhibits the proliferation and invasion by targeting IGF2BP1 in glioblastoma.

Authors:  Yonggang Luo; Ranran Sun; Jun Zhang; Tongwen Sun; Xianzhi Liu; Bo Yang
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

8.  Gastric adenocarcinoma microRNA profiles in fixed tissue and in plasma reveal cancer-associated and Epstein-Barr virus-related expression patterns.

Authors:  Amanda L Treece; Daniel L Duncan; Weihua Tang; Sandra Elmore; Douglas R Morgan; Ricardo L Dominguez; Olga Speck; Michael O Meyers; Margaret L Gulley
Journal:  Lab Invest       Date:  2016-03-07       Impact factor: 5.662

9.  microRNA-762 promotes breast cancer cell proliferation and invasion by targeting IRF7 expression.

Authors:  Yongping Li; Ruixue Huang; Ling Wang; Junsheng Hao; Qiong Zhang; Rui Ling; Jun Yun
Journal:  Cell Prolif       Date:  2015-11-02       Impact factor: 6.831

10.  miR-372 suppresses tumour proliferation and invasion by targeting IGF2BP1 in renal cell carcinoma.

Authors:  Xuan Huang; Mingjie Huang; Lingbao Kong; Yong Li
Journal:  Cell Prolif       Date:  2015-10       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.